Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554172 | 0.92 | NAMPT (0.42) | NAMPTPKMLMNASMN1; SMN2ROCK2 | |
| SCHEMBL3550434 | 0.90 | AVPR1A (0.42) | NAMPTPKMLMNASMN1; SMN2DRD2 | |
| SCHEMBL3554157 | 0.89 | DGAT2 (0.44) | NAMPTPKMLMNASMN1; SMN2ROCK2 | |
| SCHEMBL3555113 | 0.89 | NAMPT (0.40) | NAMPTPKMLMNASMN1; SMN2ROCK2 | |
| SCHEMBL3550256 | 0.89 | USP2 (0.45) | NAMPTPKMLMNASMN1; SMN2ROCK2 | |
| SCHEMBL3553328 | 0.89 | AVPR2 (0.40) | NAMPTPKMLMNASMN1; SMN2ROCK2 | |
| SCHEMBL3553530 | 0.89 | HTT (0.43) | NAMPTLMNASMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL3552860 | 0.88 | LMNA (0.42) | NAMPTPKMLMNAALDH1A1GAA | |
| SCHEMBL3558808 | 0.88 | AVPR2 (0.45) | NAMPTROCK2ALDH1A1GAAPOLB | |
| SCHEMBL3559955 | 0.88 | NAMPT (0.41) | NAMPTPKMLMNASMN1; SMN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678787-B2 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-03-16 | — | — | US | claimed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | claimed |
| US-7678787-B2 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, PRLHR | NAMPT 1960/4885PKM 2716/4885LMNA 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.